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There is abundant evidence for tumor-directed cellular immunity in a variety
of human tumors (1-7). The continuing high mortality from cancer indicates, how-
ever, that the capacity of host mechanisms of this kind to limit the growth of estab-
lished tumors and inhibit metastasis formation is strictly limited. Considerable
effort is presently being expended in numerous centers in an effort to devise
methods which will improve the level of such responses. By corollary the identifica-
tion and avoidance of techniques and materials which might reduce host respon-
siveness seems a worthwhile aim which might yield practical results in the short
term.
It is well-known to surgeons that cancer surgery in an unpredictable minority
of patients may be followed by rapid development of metastases. In this context
the demonstration of depressed lymphocyte function, as evidenced by a reduced
capacity to transform on exposure to phytomitogens (8-10) was of considerable
interest. We have recently reported a (11 ) temporary loss of tumor-directed cellu-
lar immunity in patients undergoing surgery for malignant melanoma or breast car-
cinoma in the immediate postoperative period. This paper describes the present
status of this continuing study in the patients with malignant melanoma.
MATERIALS AND METHODS
The patients all attended hospitals in the Glasgow area and all had histologically
proved malignant melanoma.
The technique employed to assay cellular immunity and the method of preparing
tumor extracts for use as antigens and statistical methods employed have been
previously described in detail ( 1).
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RESULTS
Summary of Findings in a Study of Cellular Immunity to Malignant Melanoma
It is not the purpose of this paper to give a detailed account of cellular immunity
in melanoma patients, but to set the main findings in context we have included
Table 1. The salient features are:
(1) Malignant melanoma extracts inhibited the migration of autologous leuko-
cytes in 8 of 10 cases studied.
(2) In homologous combinations, the leukocytes of 33 of 55 melanoma patients
showed inhibition on contact with melanoma extracts.
(3) There is a progressive diminution in the frequency of migration inhibition
with advancing clinical stage.
(4) Melanoma patients' leukocytes were infrequently inhibited by contact with
extracts of neoplastic and nonneoplastic breast conditions.
(5) Control donors' leukocytes showed almost no migration inhibition when
exposed to melanoma extracts.
Patients Studied While Undergoing Operation and in the Postoperative
Period (Table 2)
Twenty-two patients undergoing operation for malignant melanoma were
studied. The operations were for excision of a primary tumor (18), of an enlarged
tumor containing lymph nodes (2), and for removal of subcutaneous recurrent
TABLE 1
THE FREQUENCY OF MIGRATION INIIIBITION OF TIIE LEUKOCYTES OF PATIENTS WNJTII
MALIGNANT MELANOMA AND OF CONTROL DONORs EXPOSED TO EXTRACTS OF
MALIGNANT MELANOMAS AND NEOPLASTIC AND NONNEOIPLASTIC
BREAST DISEASEa
Cell donor Mtelaniomla extracts Br-east extr-acts
Malignant melanoma (autologous) 8/10 (80)
Malignant melanoma (homologous) 33/55 (60) 1/172 (8)
Malignant melanoma (primary) 24/37 (65)
Malignant melanoma (lymph nodes) 7/15 (47)
Malignant melanoma (blood-spread) 0/6 (0)
Control donors 9/63 (14)
a Frequency of individuals with a positive reaction/total number of individuals tested. Figures in
parentheses are percentages.
TABLE '2
THE FREQUENCY OF POSITIVE AND NEGATIVE LEUKOCYTE-MIIGRATION TESTS IN PATIENTS
WITH MALIGNANT MELANOMA EXAMINED BEFORE AND AFTER SUIRGICAL TREATMENTa
Patients tested ill
Preoperative Immediate post- Later postoperative Time to return of
period operative periodb period reactivity (days)
+ve -ve +ve -ve +ve -ve Mean Range
12/16 4/16 1/22 21/22 15/19 4/19 10.6 5-22
a Patients with positive or negative reactions/total patients tested at each stage.
b Days 1-4 after operation.
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nodules (2). They lasted from 30-90 min. The premedicating agents were usually
morphine and scopolamine; anesthetic agents included nitrous oxide, halothane,
and thiopentone sodium sometimes in association with suxamethonium.
Sixteen patients were tested before operation with autologous and/or homolo-
gous melanoma extracts and in 12 cases the migration of peripheral blood leuko-
cytes was inhibited. All 22 patients were tested in the immediate postoperative
period and in all but one there was no migration inhibition on contact with
melanoma extracts. In the single exceptional case a preoperative test was negative,
a test on the second postoperative day was positive, and one 42 days after opera-
tion was negative. Nineteen patients were tested at various times after the imme-
diate postoperative period in 15 of whom a positive reaction returned, usually in
the second postoperative week (mean 10.6 days), but with a range of 5-22 days
postoperatively. One patient (not shown in the table) had three successive opera-
tions at weekly intervals. This patient gave a positive reaction before the first opera-
tion but successive tests were negative until 7 days after the third operation when
positive reactivity returned and remained during subsequent tests. One patient was
observed over three operations and gave a positive reaction before each. Reactivity
was lost in the immediate postoperative phase but was observed on the sixth post-
operative day on two occasions. Of the four patients who did not show a return
of reactivity two are alive, well, and apparently tumor-free 8 and 6 months after
operation, one was tested for only a short time after operation and one died of
disseminated malignant melanoma 2 months after operation.
Comparison of Blood Cortisol Levels and Variations in Migration Inhibition
Blood cortisol levels were assayed for four patients. The expected rise was ob-
served in all four, developing during the operation and persisting for approximately
2 days. In all four patients cortisol levels had returned to normal by Day 3 after
operation. In all patients there was a postoperative loss of leukocyte-migration in-
hibition observed preoperatively. Inhibition comparable to that observed preopera-
tively was observed in two patients on Day 5 after operation and in one on Day
8 after operation. In the fourth patient there was no return of inhibition and the
patient died of disseminated melanoma 2 months after operation.
DISCUSSION
These results extended our previous observations (11, 12) of (usually) transient
postoperative loss of tumor-directed cellular immunity to a larger series of patients.
Further interest in this phenomenon falls broadly into attempts to assess its sig-
nificance and attempts to analyze its mechanism.
In theory it is possible that this loss of cellular reactivity, at a time when small
numbers of tumor cells may be disseminated to a greater or lesser degree by opera-
tive trauma, may be highly relevant to the processes of metastasis formation. In
the absence of effective cytotoxic lymphoid cells such scattered tumor cells could
become coated by noncytotoxic antibodies which would effectively protect the
tumor cells when potentially cytotoxic lymphoid cells were restored to normal func-
tion. It is difficult to test such a hypothesis in man and we have, therefore, insti-
tuted animal studies designed to answer these questions.
Gershon and his associates have also described a situation in which tumor re-
moval in animals is followed by a loss of demonstrable tumor-directed cellular im-
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munity (13-15). These findings were, however, confined to a relatively limited pe-
riod after tumor transplantation and the loss of reactivity was stable although it
could be overcome by rechallenge with tumor. We thus believe that our observa-
tions represent a separate, though perhaps related, phenomenon. Barski and Youn
(16) reported on the effect of tumor excision on tumor-directed cellular immunity
in mice and found that while reactivity was not demonstrable immediately preop-
eratively or in the first postoperative week it could be shown to be present when
mice were examined 7-21 days after operation. While the great majority of patients
in our present study behaved otherwise, there were four individuals who gave a
negative reaction preoperatively and in the immediate postoperative phase but who
gave a positive response in later tests.
The question of mechanism is also unsettled. Obviously the medication adminis-
tered before and during anesthesia and the multiple metabolic changes consequent
upon operative trauma must be investigated.
The anesthetics and premedicative materials used on the patients of this series
are commonly employed agents, there are, however, a number of reports that anes-
thetic agents, including halothane and even nitrous oxide, may have transient but
significant depressive activity against lymphocytes (17-20).
Preliminary results with blood leukocytes obtained during operation, when anes-
thetic concentrations are maximal, are conflicting. In a small number of patients
with breast carcinoma examined at this time we have not demonstrated leukocyte-
migration inhibition on contact with autologous and homologous tumor extracts.
In studies using Purified Protein Derivative (PPD) and leukocytes taken from
PPD-sensitive donors, however, inhibition comparable in degree to that seen pre-
operatively has been observed (Lindop and Bancewicz, unpublished data). These
latter observations, while suggesting that the presence of a high concentration of
anesthetic does not directly reduce migration inhibition, do not, however, exclude
a delayed effect of anesthetic agents as the cause of the postoperative loss of migra-
tion inhibition.
The postoperative phase is characterized by numerous alterations in the bio-
chemistry of the blood and tissue fluids. Many of the materials present in altered
concentration, hormones, enzymes, products of tissue breakdown are highly active
pharmacologically and could individually or collectively alter lymphocyte function.
It is also clear that only a transient rise in these components may bring about a
relatively long-lasting alteration in lymphocyte function. We have examined the
well-known postoperative rise of adrenal cortical steroid levels in the body, as a
possible mechanism for the observed phenomenon. The kinetics of this rise and
of the loss of migration inhibition suggest that if this is indeed the mechanism,
the effect of steroids on lymphocytes must be of rather long duration. The complex
mechanism of steroid-mediated influences on the leukocyte-migration test is sug-
gested by Stevenson (21) who showed both direct and indirect effects on cell
motility, probably mediated by a lymphocyte-lymphokine type of mechanism.
SUMMARY
In a study using the leukocyte-migration test the leukocytes of a majority of
melanoma patients were inhibited by contact with autologous or homologous
melanoma extracts. Repeat testing of the same patients' leukocytes during the first
4 days after operation showed a complete loss of reactivity in all but one individual.
Reactivity returned to preoperative levels in most patients 7-10 days after opera-
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tion. The mechanism and significance of this transient loss of cellular immunity
are discussed.
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